1.Effect of IGFBP7 overexpression on proliferation of human hepatocellular carcinoma HepG2 cells
Liyao WEI ; Manyi YANG ; Fangming WU ; Hongjuan XU ; Jian PENG
Journal of Chinese Physician 2016;(z1):12-14
Objective To present study was to investigate the effects of insulin-like growth factor binding protein 7 (IGFBP7)on the proliferation of human hepatocellular carcinoma HepG2 cells.Methods Human hepatocellular carcinoma HepG2 cells was cultured,and plasmid pIRES2-ZsGreen1-IGFBP7 or empty plasmid was transfected into HepG2 cells and the cell transfection efficiency was examined by fluores-cence microscopy;MTT was performed to evaluate the effect of IGFBP7 on proliferation and apoptosis of HepG2 cells in 48 hours after transfection.Results IGFBP7 transfected group decreased cell proliferation noticeably.Conclusions Overexpression of IGFBP7 can down-regulte the proliferation of human hepatocel-lular carcinoma HepG2 cells.
2.Clinical features of transthyretin amyloid polyneuropathy caused by Ser77Tyr mutation
Zengchang YUE ; Linqing ZHONG ; Jianming ZHENG ; Liyao WEI
Chinese Journal of Neuromedicine 2023;22(9):923-927
Objective:To study the clinical features of transthyretin amyloid polyneuropathy (ATTR-PN) caused by Ser77Tyr mutation.Methods:The clinical data of a patient with ATTR-PN caused by Ser77Tyr mutation, admitted to our hospital from Department of Neurology, Mindong Hospital Affiliated to Fujian Medical University, were retrospectively analyzed. Literature on patients with ATTR-PN caused by Ser77Tyr mutation in Pubmed, Web of Science, CNKI and Wanfang databases and those with ATTR-PN caused by Val30Met mutation in Pubmed and Web of Science were searched and screened, and clinical characteristics of these patients were extracted. The differences of clinical characteristics among patients with ATTR-PN caused by Ser77Tyr or Val30Met mutations were compared.Results:(1) Transthyroxin ( TTR) gene Sanger sequencing results showed Ser77Tyr heterozygous pathogenic mutation; Congo red staining of biopsy sample in the patient 2.5 years after onset showed amyloid deposition. (2) Seventy-eight patients with ATTR-PN caused by Ser77Tyr mutation were summarized, they mostly had onset at 50-60 years old; male patients had higher incidence (74.4%); most patients (78.0%) had positive family history; most patients had sensory symptoms as initial symptom (72.0%), which gradually progressed to extensive peripheral nerve involvement and combined with widespread heart damage (96.4%) over several years; electrophysiological examination mainly showed axonal damage and carpal tunnel syndrome; the tissue biopsy had high positive rate(84.8%). (3) There were 192 and 96 patients with ATTR-PN caused by early-onset and late-onset Val30Met mutations, respectively; compared with patients with ATTR-PN caused by early-onset Val30Met mutation, patients with ATTR-PN caused by Ser77Tyr mutation had significantly higher incidence of deep sensory disturbance (28.6% vs. 58.5%, P<0.05). Compared with patients with ATTR-PN caused by late-onset Val30Met mutation, patients with ATTR-PN caused by Ser77Tyr mutation had increased incidence of mild sensory disturbance (56.3% vs. 75.0%) and decreased incidence of limb weakness (65.6% vs. 48.3%), with significant differences ( P<0.05). ATTR-PN patients caused by Ser77Tyr mutation had significantly higher incidence of carpal tunnel syndrome than ATTR-PN patients caused by early-onset and late-onset Val30Met mutations (75.4% vs. 10.8% and 25.0%) and significantly higher incidence of cardiac damage than ATTR-PN patients caused by early-onset Val30Met mutation (96.4% vs. 80.5%, P<0.05). Conclusion:Ser77Tyr mutation has some distinctive clinical features: relatively balanced damage of large and small fibers, prominent carpal tunnel syndrome, and obvious heart disease; early identification of these features and administration of tissue biopsy and gene detection are helpful for early diagnosis.
3.Practice and exploration of improving the rational use of drugs in primary medical institutions by the general pharmacist system of the medical consortium
Tianran HUANGFU ; Binghong HE ; Yanhui DENG ; Meidan WEI ; Xiaoxia ZHENG ; Huancun FENG ; Liyao WU ; Weitao LU ; Wenying CHEN
China Pharmacy 2022;33(6):753-757
OBJECTIVE To explore and establis h a general pharmacist system suitable for China ’s national conditions ,and to improve the rational use of drugs in primary medical institutions . METHODS Under the leadership of Tianhe District Health Bureau of Guangzhou ,relying on the regional pharmaceutical specialty alliance ,general pharmacist system of medical consortium was established ,and the general pharmacist was responsible for the overall planning of pharmaceutical care in the medical consortium. The joint management office of pharmaceutical care was established ,and the training of the pharmacists in the medical consortium was organized. A regional audit center was established to realize the prescription review of 13 community health service centers in the medical consortium. “Internet plus ”home pharmaceutical care was carried out ,and science popularization education was provided for communities ,schools,enterprises and institutions. RESULTS After systematic training and assessment ,three pharmacist teams had been successfully established in the medical consortium to provide prescription review ,science popularization and education and family pharmacist services for community residents ;the regional audit center successfully intercepted 17.17% of unreasonable prescriptions ,reducing the amount of unreasonable drug use by a total of 6.56 million yuan. After the intervention of prescription review system ,the qualified rate of outpatient prescriptions in community health service centers was ≥95%,and the qualified rate increased by an average of 6%. The department of pharmaceutical science popularization and education held 35 science popularization and free clinic activities ,of which 71.20% of the residents believed that the activities had improved their understanding of drugs. In addition ,111 cases patients serviced by home pharmaceutical care were carried out successfully by pharmacist team ,and the patients ’acceptance of pharmacist intervention was 91.89% . CONCLUSIONS Under the new medical reform ,it is feasible to implement a regional general pharmacist system within the medical consortium , which improves the pharmaceutical administration and pharmaceuticalcare capabilities of m edical institutions in the medical consortium,as well as the level of rational drug use ,and reduces the me dical burden.